Home LiteratureArticle Details
PMID: 20699125 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation ·Vol. 16 ·No. 11 ·2010-11-00 ·Pages 1467-503

Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K

Abstract

Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

MeSH Terms
Hematologic Neoplasms/therapy Hematopoietic Stem Cell Transplantation Hodgkin Disease/therapy Humans Leukemia, Lymphocytic, Chronic, B-Cell/therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy Leukemia, Myeloid, Acute/therapy Lymphocyte Transfusion Lymphoma, Non-Hodgkin Multiple Myeloma/therapy Neoplasm Recurrence, Local/therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy Recurrence Transplantation, Homologous Treatment Failure
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Porter David L
University of Pennsylvania Medical Center, Philadelphia, 19104, USA. [email protected]
Alyea Edwin P
Antin Joseph H
DeLima Marcos
Estey Eli
Falkenburg J H Frederik
Hardy Nancy
Kroeger Nicolaus
Leis Jose
Levine John
Maloney David G
Peggs Karl
Rowe Jacob M
Wayne Alan S
Giralt Sergio
Bishop Michael R
van Besien Koen
References (316)
316 references, click to expand
  1. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation.
    Biol Blood Marrow Transplant. 2000;6(3A):321-6 PMID: 10905769
  2. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83 PMID: 16443515
  3. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Cancer. 2004 Jun 15;100(12):2583-91 PMID: 15197800
  4. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
    J Clin Oncol. 2006 Apr 1;24(10):1575-81 PMID: 16520464
  5. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    Haematologica. 2008 Mar;93(3):455-8 PMID: 18287132
  6. Epstein-Barr viral DNA in tissues of Hodgkin's disease.
    Am J Pathol. 1987 Oct;129(1):86-91 PMID: 2821817
  7. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
    Leukemia. 2003 Feb;17(2):468-70 PMID: 12592351
  8. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect.
    Bone Marrow Transplant. 2004 Sep;34(5):391-7 PMID: 15273707
  9. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Blood. 2000 Oct 15;96(8):2712-6 PMID: 11023502
  10. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing.
    J Immunol. 1996 Jun 15;156(12):4609-16 PMID: 8648103
  11. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Biol Blood Marrow Transplant. 2010 May;16(5):639-46 PMID: 20005967
  12. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2010 Mar;51(3):376-89 PMID: 20141428
  13. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    J Clin Oncol. 2003 Apr 1;21(7):1278-84 PMID: 12663715
  14. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.
    J Clin Oncol. 2000 Jun;18(11):2273-81 PMID: 10829048
  15. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.
    Leuk Lymphoma. 2004 Apr;45(4):731-3 PMID: 15160947
  16. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
    J Immunother. 2007 Nov-Dec;30(8):847-54 PMID: 18049337
  17. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
    Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25 PMID: 18342784
  18. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?
    Lancet. 1978 Sep 9;2(8089):537-40 PMID: 79913
  19. Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Br J Haematol. 2000 Sep;110(4):1013-4 PMID: 11054097
  20. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
    Blood. 2007 Feb 1;109(3):944-50 PMID: 17032921
  21. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
    Leukemia. 2009 Mar;23(3):605-7 PMID: 18784738
  22. Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy.
    Bone Marrow Transplant. 1988 Nov;3(6):619-24 PMID: 3063329
  23. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research.
    Blood. 2006 Jun 15;107(12):4961-7 PMID: 16493003
  24. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
    Leuk Res. 2009 Jan;33(1):174-7 PMID: 18471874
  25. Continuous cultures of fused cells secreting antibody of predefined specificity.
    Nature. 1975 Aug 7;256(5517):495-7 PMID: 1172191
  26. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Blood. 2009 Jun 25;113(26):6567-71 PMID: 19389879
  27. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8 PMID: 16344099
  28. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
    Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211 PMID: 20558311
  29. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Hematol J. 2004;5(1):47-54 PMID: 14745430
  30. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
    Ann Oncol. 2008 Nov;19(11):1935-40 PMID: 18684698
  31. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
    Blood. 2004 Dec 1;104(12):3535-42 PMID: 15304387
  32. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
    Haematologica. 2009 Feb;94(2):230-8 PMID: 19066328
  33. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8 PMID: 18158961
  34. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
    Leukemia. 2008 Jul;22(7):1377-86 PMID: 18418404
  35. Allogeneic transplantation for Hodgkin lymphoma.
    Br J Haematol. 2008 Nov;143(4):468-80 PMID: 18710379
  36. Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
    Leukemia. 2007 Dec;21(12):2569-74 PMID: 17611558
  37. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood. 2002 Nov 1;100(9):3108-14 PMID: 12384406
  38. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.
    Blood. 2002 Jul 15;100(2):635-9 PMID: 12091358
  39. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
    Blood. 2010 Nov 11;116(19):3875-86 PMID: 20631379
  40. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.
    Leukemia. 2008 Dec;22(12):2142-50 PMID: 18818707
  41. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
    J Clin Oncol. 1997 Feb;15(2):433-44 PMID: 9053463
  42. Perspectives on familial chronic lymphocytic leukemia: genes and the environment.
    Semin Hematol. 2004 Jul;41(3):201-6 PMID: 15269880
  43. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
    J Clin Oncol. 2008 May 20;26(15):2519-25 PMID: 18427150
  44. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Ann Hematol. 2003 Sep;82(9):548-51 PMID: 14504811
  45. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.
    Haematologica. 2003 May;88(5):555-60 PMID: 12745275
  46. Minor histocompatibility antigens in human stem cell transplantation.
    Exp Hematol. 2003 Sep;31(9):743-51 PMID: 12962719
  47. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
    J Clin Oncol. 2003 Dec 1;21(23):4407-12 PMID: 14645431
  48. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Leukemia. 2003 May;17(5):841-8 PMID: 12750695
  49. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
    Bone Marrow Transplant. 2008 May;41(9):779-84 PMID: 18195681
  50. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
    Haematologica. 2007 Mar;92(3):414-7 PMID: 17339194
  51. Loss of mismatched HLA in leukemia after stem-cell transplantation.
    N Engl J Med. 2009 Jul 30;361(5):478-88 PMID: 19641204
  52. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65 PMID: 12720218
  53. Involved field radiation therapy and donor lymphocyte infusion for relapsed or refractory non-Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2008 Nov;88(4):463-464 PMID: 18836792
  54. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Blood. 1998 May 15;91(10):3671-80 PMID: 9573003
  55. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).
    Br J Haematol. 2000 Feb;108(2):400-7 PMID: 10691873
  56. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Blood. 2002 Nov 1;100(9):3121-7 PMID: 12384408
  57. Donor leukocyte infusions for multiple myeloma.
    Bone Marrow Transplant. 2000 Dec;26(11):1179-84 PMID: 11149728
  58. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.
    Blood. 2007 Apr 15;109(8):3588-94 PMID: 17158231
  59. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Bone Marrow Transplant. 2003 Jun;31(11):973-9 PMID: 12774047
  60. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
    Blood. 2000 Mar 1;95(5):1572-9 PMID: 10688810
  61. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
    Biol Blood Marrow Transplant. 2002;8(11):625-32 PMID: 12463482
  62. Bendamustine: rebirth of an old drug.
    J Clin Oncol. 2009 Mar 20;27(9):1492-501 PMID: 19224851
  63. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.
    Blood. 1991 Apr 1;77(7):1423-8 PMID: 2009366
  64. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Eur J Haematol. 2009 Jan;82(1):61-8 PMID: 18801058
  65. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
    Blood. 2004 Oct 15;104(8):2600-2 PMID: 15205268
  66. Infusion of donor-derived peripheral blood leukocytes after transplantation of cord blood progenitor cells can increase the graft-versus-leukaemia effect.
    Leukemia. 1997 May;11(5):729-31 PMID: 9180299
  67. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
    Cancer Res. 2010 May 15;70(10):3915-24 PMID: 20424114
  68. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
    Lancet. 2005 Jun 4-10;365(9475):1934-41 PMID: 15936420
  69. [Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation].
    Rinsho Ketsueki. 1997 Aug;38(8):643-6 PMID: 9311269
  70. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
    Blood. 2008 Nov 1;112(9):3807-17 PMID: 18599795
  71. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Transplantation. 2004 Feb 15;77(3):391-8 PMID: 14966413
  72. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
    Bone Marrow Transplant. 1996 Sep;18(3):669-72 PMID: 8879640
  73. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
    Cancer. 2009 Dec 1;115(23):5490-8 PMID: 19708032
  74. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
    Blood. 2010 May 13;115(19):3869-78 PMID: 20071660
  75. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
    Blood. 2005 May 15;105(10):3945-50 PMID: 15692072
  76. New designs for phase 2 clinical trials.
    Blood. 2003 Jul 15;102(2):442-8 PMID: 12560224
  77. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
    Blood. 2008 Oct 15;112(8):3500-7 PMID: 18664621
  78. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clin Exp Immunol. 2007 Jun;148(3):520-8 PMID: 17493020
  79. Genetically identical twin transplantation for chronic lymphocytic leukemia.
    Leukemia. 2007 Dec;21(12):2452-5 PMID: 17728782
  80. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Blood. 2005 Mar 15;105(6):2473-9 PMID: 15572591
  81. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    J Clin Oncol. 2003 Jul 15;21(14):2747-53 PMID: 12860954
  82. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.
    Blood. 2007 Oct 1;110(7):2761-3 PMID: 17579184
  83. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
    Blood. 2004 Feb 1;103(3):790-5 PMID: 14525766
  84. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
    Bone Marrow Transplant. 2010 Feb;45(2):349-53 PMID: 19584825
  85. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Biologics. 2008 Dec;2(4):717-24 PMID: 19707452
  86. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
    Blood. 2006 Feb 15;107(4):1724-30 PMID: 16239425
  87. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
    Blood. 2009 Feb 12;113(7):1581-8 PMID: 18974373
  88. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    J Clin Oncol. 2005 Mar 20;23(9):1993-2003 PMID: 15774790
  89. Donor leukocyte infusions in acute myelogenous leukemia.
    Leukemia. 2003 Jun;17(6):1035-7 PMID: 12764364
  90. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
    Leukemia. 2004 Mar;18(3):659-62 PMID: 14671630
  91. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
    Haematologica. 2008 Feb;93(2):303-6 PMID: 18245655
  92. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.
    Vaccine. 2007 Nov 14;25(46):7955-61 PMID: 17933439
  93. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97 PMID: 18940684
  94. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
    Blood. 2001 Aug 15;98(4):934-9 PMID: 11493435
  95. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Biol Blood Marrow Transplant. 2007 Oct;13(10):1160-8 PMID: 17889352
  96. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Bone Marrow Transplant. 2009 Nov;44(9):585-8 PMID: 19363531
  97. Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run.
    J Clin Oncol. 2008 Nov 10;26(32):5151-3 PMID: 18824700
  98. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.
    Biol Blood Marrow Transplant. 2005 Nov;11(11):823-61 PMID: 16275588
  99. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Leuk Lymphoma. 2009 Aug;50(8):1239-48 PMID: 19562639
  100. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.
    Leukemia. 2004 Jan;18(1):165-6 PMID: 14603333
  101. Remission of adult acute lymphocytic leukaemia with alemtuzumab.
    Leukemia. 2004 Sep;18(9):1557-8 PMID: 15229619
  102. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
    Bone Marrow Transplant. 2006 Jun;37(12):1135-41 PMID: 16757975
  103. Donor leukocyte infusions in myeloid malignancies: new strategies.
    Best Pract Res Clin Haematol. 2006;19(4):737-55 PMID: 16997180
  104. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
    Blood. 2009 Aug 13;114(7):1429-36 PMID: 19528536
  105. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Clin Cancer Res. 2008 Nov 1;14(21):6907-15 PMID: 18980985
  106. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
    N Engl J Med. 1979 May 10;300(19):1068-73 PMID: 34792
  107. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation.
    Br J Haematol. 1997 Apr;97(1):165-8 PMID: 9136960
  108. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
    Eur J Clin Invest. 2009 Dec;39(12):1098-109 PMID: 19744184
  109. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
    Clin Cancer Res. 2010 Mar 15;16(6):1894-903 PMID: 20215554
  110. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
    Mol Ther. 2010 Apr;18(4):843-51 PMID: 20179677
  111. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.
    Br J Haematol. 2001 Feb;112(2):421-3 PMID: 11167841
  112. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies.
    Leuk Lymphoma. 2006 Jun;47(6):978-85 PMID: 16840186
  113. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
    Blood. 2004 Dec 1;104(12):3797-803 PMID: 15280203
  114. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
    Blood. 2008 Jun 1;111(11):5291-7 PMID: 18334676
  115. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.
    J Clin Oncol. 1996 Feb;14(2):572-8 PMID: 8636773
  116. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
    Bone Marrow Transplant. 2010 Apr;45(4):627-32 PMID: 19718057
  117. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
    Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46 PMID: 20637879
  118. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
    J Clin Oncol. 2008 Jan 10;26(2):211-7 PMID: 18056679
  119. [Remission induction of refractory diffuse large B-cell lymphoma with allogeneic peripheral blood stem cell transplantation followed by interferon-alpha and donor lymphocyte infusion].
    Rinsho Ketsueki. 2004 Feb;45(2):155-60 PMID: 15045825
  120. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
    Leuk Lymphoma. 2007 Oct;48(10):1931-9 PMID: 17917961
  121. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.
    Bone Marrow Transplant. 2003 Oct;32(8):835-42 PMID: 14520431
  122. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
    Blood. 2005 Apr 1;105(7):2973-8 PMID: 15613541
  123. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    J Exp Med. 2004 Dec 20;200(12):1623-33 PMID: 15611290
  124. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.
    Transfusion. 2007 Mar;47(3):520-8 PMID: 17319835
  125. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.
    Blood. 2008 Jan 1;111(1):446-52 PMID: 17916744
  126. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
    Blood. 2007 Jun 15;109(12):5136-42 PMID: 17344466
  127. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Bone Marrow Transplant. 2005 May;35(10):943-51 PMID: 15806128
  128. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.
    Cancer Immunol Immunother. 2008 Nov;57(11):1705-10 PMID: 18663443
  129. Diagnostic criteria for monoclonal B-cell lymphocytosis.
    Br J Haematol. 2005 Aug;130(3):325-32 PMID: 16042682
  130. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.
    Blood. 2006 May 1;107(9):3804-7 PMID: 16384924
  131. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Blood. 2005 Jul 15;106(2):458-63 PMID: 15817679
  132. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
    Br J Haematol. 2007 Dec;139(5):824-31 PMID: 18021093
  133. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
    Bone Marrow Transplant. 2008 Aug;42(3):201-5 PMID: 18490913
  134. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
    Science. 2008 Aug 15;321(5891):974-7 PMID: 18703743
  135. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.
    Blood. 1991 Feb 1;77(3):649-53 PMID: 1991174
  136. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions.
    Curr Opin Hematol. 2002 Nov;9(6):503-8 PMID: 12394172
  137. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
    Blood. 1995 Mar 15;85(6):1580-9 PMID: 7888675
  138. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
    Bone Marrow Transplant. 2005 Sep;36(5):437-41 PMID: 15980879
  139. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
    Blood. 2009 Jan 15;113(3):726-32 PMID: 18945962
  140. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766-70 PMID: 1647016
  141. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2008 Mar;41(5):483-93 PMID: 18026156
  142. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
    Bone Marrow Transplant. 2009 Jan;43(2):107-13 PMID: 18776928
  143. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Cancer Res. 2007 Jun 1;67(11):5489-97 PMID: 17545631
  144. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
    Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 PMID: 12601144
  145. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
    Biol Blood Marrow Transplant. 2009 May;15(5):610-7 PMID: 19361753
  146. Donor leukocyte infusions in acute lymphocytic leukemia.
    Bone Marrow Transplant. 2000 Sep;26(5):511-6 PMID: 11019840
  147. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia.
    Exp Hematol. 2004 Jun;32(6):556-62 PMID: 15183896
  148. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
    Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28 PMID: 20227509
  149. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.
    Bone Marrow Transplant. 1993 Feb;11(2):109-11 PMID: 8435660
  150. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Science. 2002 Mar 15;295(5562):2097-100 PMID: 11896281
  151. Adoptive cellular immunotherapy with CD19-specific T cells.
    Klin Padiatr. 2005 Nov-Dec;217(6):351-6 PMID: 16307422
  152. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2010 Aug;150(3):352-8 PMID: 20528877
  153. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
    J Clin Oncol. 2009 Jan 20;27(3):426-32 PMID: 19064981
  154. Second allogeneic transplantation after failure of first autologous transplantation.
    Biol Blood Marrow Transplant. 2000;6(3):272-9 PMID: 10871152
  155. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
    J Clin Oncol. 2009 Dec 10;27(35):6012-8 PMID: 19826119
  156. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
    Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5 PMID: 15148407
  157. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children.
    Bone Marrow Transplant. 1997 Apr;19(7):697-702 PMID: 9156247
  158. Donor lymphocyte infusions: the long and winding road: how should it be traveled?
    Bone Marrow Transplant. 2008 Nov;42(9):569-79 PMID: 18711351
  159. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.
    Blood. 1996 Oct 1;88(7):2787-93 PMID: 8839877
  160. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
    Blood. 2007 Feb 1;109(3):1103-12 PMID: 17023585
  161. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.
    Biol Blood Marrow Transplant. 1999;5(4):253-61 PMID: 10465105
  162. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Cancer Treat Rev. 2009 Dec;35(8):653-61 PMID: 19682801
  163. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?
    J Clin Immunol. 2002 May;22(3):124-30 PMID: 12078853
  164. Graft-versus-leukemia effects of transplantation and donor lymphocytes.
    Blood. 2008 Dec 1;112(12):4371-83 PMID: 19029455
  165. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma.
    Br J Haematol. 2008 Sep;142(5):848-50 PMID: 18631344
  166. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation.
    Bone Marrow Transplant. 1994 Aug;14(2):331-2 PMID: 7994252
  167. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2002 Sep;43(9):1755-62 PMID: 12685828
  168. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia.
    Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 PMID: 12599176
  169. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.
    Blood. 1997 Nov 15;90(10):4206-11 PMID: 9354693
  170. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
    J Clin Oncol. 2005 Jun 1;23(16):3819-29 PMID: 15809448
  171. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Exp Hematol. 2006 Jun;34(6):770-5 PMID: 16728282
  172. Graft-versus-leukemia after second allogeneic bone marrow transplantation.
    Blood. 1994 Dec 1;84(11):3983 PMID: 7949156
  173. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
    J Clin Oncol. 2005 May 20;23(15):3433-8 PMID: 15809449
  174. Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis.
    Br J Haematol. 2003 Feb;120(3):523-5 PMID: 12580972
  175. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.
    Blood. 2006 Feb 15;107(4):1325-31 PMID: 16269610
  176. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
    Blood. 2001 Jul 1;98(1):210-6 PMID: 11418482
  177. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
    J Clin Oncol. 2001 Dec 1;19(23):4314-21 PMID: 11731514
  178. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.
    Blood. 2002 Oct 1;100(7):2289-90 PMID: 12239136
  179. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    J Clin Oncol. 2007 Nov 1;25(31):4938-45 PMID: 17909197
  180. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2009 Apr;50(4):551-8 PMID: 19373652
  181. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
    Mol Ther. 2007 May;15(5):981-8 PMID: 17375070
  182. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
    Cancer. 2009 May 1;115(9):1899-905 PMID: 19235255
  183. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect.
    Biol Blood Marrow Transplant. 2008 Apr;14(4):480-3 PMID: 18342792
  184. Immunotherapy of hematologic malignancy.
    Hematology Am Soc Hematol Educ Program. 2003;:331-49 PMID: 14633789
  185. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.
    Blood. 2006 Jun 1;107(11):4563-9 PMID: 16449533
  186. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Leukemia. 2004 Nov;18(11):1789-97 PMID: 15385924
  187. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.
    Biol Blood Marrow Transplant. 2010 Sep;16(9):1237-44 PMID: 20302960
  188. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2010 Mar;45(3):558-64 PMID: 19633691
  189. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    Blood. 2006 Apr 15;107(8):3415-6 PMID: 16597603
  190. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Br J Haematol. 2005 Feb;128(4):496-502 PMID: 15686458
  191. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
    Blood. 1999 Aug 15;94(4):1201-8 PMID: 10438707
  192. B-cell involvement in chronic graft-versus-host disease.
    Haematologica. 2008 Nov;93(11):1702-11 PMID: 18728020
  193. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients.
    Bone Marrow Transplant. 2005 Mar;35(6):549-56 PMID: 15756282
  194. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.
    J Clin Oncol. 1989 Jan;7(1):50-7 PMID: 2642540
  195. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion.
    Bone Marrow Transplant. 2009 Mar;43(5):383-97 PMID: 18850012
  196. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells.
    Blood. 1991 Sep 1;78(5):1162-5 PMID: 1652308
  197. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
    Blood. 1995 Aug 15;86(4):1261-8 PMID: 7632930
  198. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
    Blood. 1994 Nov 1;84(9):3148-57 PMID: 7949187
  199. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
    Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21 PMID: 16545725
  200. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
    Leukemia. 1999 Dec;13(12):2079-86 PMID: 10602432
  201. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    J Clin Oncol. 2001 Mar 1;19(5):1414-20 PMID: 11230486
  202. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
    Blood. 2007 Oct 15;110(8):2838-45 PMID: 17609424
  203. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
    Blood. 2010 Oct 7;116(14):2438-47 PMID: 20595516
  204. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
    Biol Blood Marrow Transplant. 2010 Mar;16(3):301-10 PMID: 19744571
  205. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
    Blood. 2009 Apr 30;113(18):4144-52 PMID: 19168784
  206. Survivin, cancer networks and pathway-directed drug discovery.
    Nat Rev Cancer. 2008 Jan;8(1):61-70 PMID: 18075512
  207. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
    Exp Hematol. 2004 Jan;32(1):28-35 PMID: 14725898
  208. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.
    J Clin Oncol. 2001 Aug 15;19(16):3675-84 PMID: 11504749
  209. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Bone Marrow Transplant. 2005 Aug;36(4):315-23 PMID: 15968284
  210. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
    Br J Haematol. 2008 Apr;141(2):235-43 PMID: 18318762
  211. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
    Blood. 2008 Feb 1;111(3):1594-602 PMID: 18032710
  212. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
    J Clin Oncol. 1993 Dec;11(12):2342-50 PMID: 8246023
  213. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
    Blood. 2004 Nov 15;104(10):3361-3 PMID: 15292062
  214. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
    Blood. 1995 Feb 15;85(4):1122-31 PMID: 7849300
  215. Extramedullary sites of leukemia relapse after transplant.
    Leuk Lymphoma. 2006 Sep;47(9):1754-67 PMID: 17064985
  216. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
    J Clin Oncol. 2005 Jun 20;23(18):4070-8 PMID: 15767647
  217. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
    N Engl J Med. 1994 Jan 13;330(2):100-6 PMID: 8259165
  218. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology.
    Biol Blood Marrow Transplant. 2004 Sep;10(9):579-90 PMID: 15319770
  219. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
    J Immunol. 1997 Dec 15;159(12):5921-30 PMID: 9550389
  220. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
    Clin Immunol. 2008 Jun;127(3):280-5 PMID: 18337174
  221. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
    Leukemia. 2006 Mar;20(3):542-5 PMID: 16408097
  222. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.
    Bone Marrow Transplant. 1992 Oct;10(4):391-5 PMID: 1422499
  223. What is the role for donor natural killer cells after nonmyeloablative conditioning?
    Biol Blood Marrow Transplant. 2009 May;15(5):580-8 PMID: 19361750
  224. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
    Bone Marrow Transplant. 2008 Aug;42(3):145-57 PMID: 18587431
  225. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.
    Blood. 2004 May 15;103(10):3982-5 PMID: 14764538
  226. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
    Blood. 2003 Oct 15;102(8):2892-900 PMID: 12829610
  227. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes.
    Bone Marrow Transplant. 1997 Mar;19(5):461-6 PMID: 9052912
  228. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
    Blood. 2004 Sep 15;104(6):1793-800 PMID: 15172969
  229. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
    Bone Marrow Transplant. 2008 Mar;41(5):495-503 PMID: 17952130
  230. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
    Mol Ther. 2010 Apr;18(4):666-8 PMID: 20357779
  231. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
    Blood. 1995 Sep 1;86(5):2041-50 PMID: 7655033
  232. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
    Bone Marrow Transplant. 2003 May;31(9):739-46 PMID: 12732878
  233. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.
    Bone Marrow Transplant. 1998 Oct;22(7):639-43 PMID: 9818690
  234. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.
    Blood. 2008 Nov 1;112(9):3574-81 PMID: 18606875
  235. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Blood. 1997 Oct 1;90(7):2549-54 PMID: 9326220
  236. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Haematologica. 2006 Dec;91(12):1653-61 PMID: 17145602
  237. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Blood. 2008 Sep 1;112(5):1876-85 PMID: 18591381
  238. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85 PMID: 19744569
  239. Graft-versus-myeloma effect in two cases.
    Lancet. 1996 Mar 23;347(9004):800-1 PMID: 8622337
  240. Immune defects in patients with chronic lymphocytic leukemia.
    Cancer Immunol Immunother. 2006 Feb;55(2):197-209 PMID: 16025268
  241. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
    Blood. 2008 Jun 15;111(12):5530-6 PMID: 18411419
  242. Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature.
    Leuk Res. 2009 Jul;33(7):e61-3 PMID: 19157550
  243. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
    J Clin Oncol. 2006 Dec 1;24(34):5343-9 PMID: 17088571
  244. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    J Clin Oncol. 2007 Mar 20;25(9):1114-20 PMID: 17296974
  245. Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.
    Haematologica. 2009 Feb;94(2):296-8 PMID: 19109219
  246. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect.
    Leukemia. 1997 Feb;11(2):281-3 PMID: 9009093
  247. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 PMID: 17084369
  248. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
    Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 PMID: 15381769
  249. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
    Bone Marrow Transplant. 2009 Jun;43(11):839-43 PMID: 19151791
  250. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
    Bone Marrow Transplant. 1997 May;19(10):977-82 PMID: 9169641
  251. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.
    Br J Haematol. 1988 Nov;70(3):317-20 PMID: 3061443
  252. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
    Br J Haematol. 2005 Jun;129(5):631-43 PMID: 15916686
  253. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
    Blood. 2004 Dec 15;104(13):3865-71 PMID: 15304395
  254. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.
    J Clin Oncol. 2002 Jan 15;20(2):405-12 PMID: 11786567
  255. Salvage therapy for CLL and the role of stem cell transplantation.
    Hematology Am Soc Hematol Educ Program. 2005;:292-8 PMID: 16304394
  256. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation.
    Blood. 2009 Mar 26;113(13):2902-5 PMID: 19179301
  257. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    J Clin Oncol. 2008 Oct 20;26(30):4912-20 PMID: 18794548
  258. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Cancer. 2006 Apr 1;106(7):1569-80 PMID: 16502413
  259. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
    Blood. 2000 Feb 15;95(4):1214-21 PMID: 10666193
  260. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
    Blood. 1990 Dec 15;76(12):2462-5 PMID: 2265242
  261. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Pediatr Blood Cancer. 2009 Feb;52(2):177-81 PMID: 18816698
  262. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
    Haematologica. 2008 Feb;93(2):257-64 PMID: 18223284
  263. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
    Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30 PMID: 19717467
  264. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Blood. 2007 Jan 15;109(2):399-404 PMID: 17003373
  265. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Exp Hematol. 1995 Dec;23(14):1553-62 PMID: 8542946
  266. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
    Lancet. 1995 Apr 22;345(8956):1016-20 PMID: 7723498
  267. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.
    Blood. 2004 Feb 15;103(4):1548-56 PMID: 14576063
  268. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
    Blood. 2003 Oct 1;102(7):2379-86 PMID: 12791647
  269. Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.
    Leuk Lymphoma. 2009 Dec;50(12):2075-7 PMID: 19637088
  270. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
    Blood. 2008 Feb 15;111(4):1827-33 PMID: 18048644
  271. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
    Exp Hematol. 2009 Jan;37(1):135-42 PMID: 19100523
  272. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Blood. 2007 Oct 1;110(7):2620-30 PMID: 17507664
  273. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
    Bone Marrow Transplant. 2004 Jul;34(2):123-8 PMID: 15133487
  274. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
    Bone Marrow Transplant. 2005 Jan;35(2):165-9 PMID: 15531895
  275. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
    J Clin Oncol. 2008 Aug 1;26(22):3756-62 PMID: 18669463
  276. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
    Blood. 2003 Feb 15;101(4):1637-44 PMID: 12393484
  277. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Br J Haematol. 2007 Oct;139(1):70-80 PMID: 17854309
  278. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.
    J Clin Oncol. 1999 Jan;17(1):208-15 PMID: 10458235
  279. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
    Bone Marrow Transplant. 2004 Oct;34(8):721-7 PMID: 15322568
  280. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Blood. 2007 Oct 1;110(7):2744-8 PMID: 17595333
  281. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
    Blood. 2004 Feb 1;103(3):784-9 PMID: 14551141
  282. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Blood. 1995 Dec 1;86(11):4337-43 PMID: 7492795
  283. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.
    Blood. 2004 Jun 1;103(11):4362-4 PMID: 14976044
  284. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Bone Marrow Transplant. 2003 Feb;31(3):157-61 PMID: 12621475
  285. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis.
    Blood. 1997 Aug 15;90(4):1664-72 PMID: 9269787
  286. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Leuk Lymphoma. 2000 Jul;38(3-4):221-34 PMID: 10830730
  287. Graft-versus-leukemia reactions after bone marrow transplantation.
    Blood. 1990 Feb 1;75(3):555-62 PMID: 2297567
  288. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
    Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23 PMID: 18541202
  289. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
    Leukemia. 2006 Jun;20(6):1040-6 PMID: 16525495
  290. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
    J Clin Oncol. 2004 May 1;22(9):1696-705 PMID: 15117992
  291. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
    Leukemia. 2008 May;22(5):1007-17 PMID: 18323802
  292. Graft-versus-myeloma effect: proof of principle.
    Blood. 1996 Feb 1;87(3):1196-8 PMID: 8562947
  293. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
    Blood. 2005 Dec 15;106(13):4389-96 PMID: 16131571
  294. Second hematopoietic stem cell transplantation in myeloid malignancies.
    Curr Opin Hematol. 2009 Mar;16(2):112-23 PMID: 19468273
  295. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.
    Blood. 1996 Jul 1;88(1):41-8 PMID: 8704200
  296. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
    J Pediatr Hematol Oncol. 2003 Apr;25(4):327-9 PMID: 12679650
  297. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
    Leukemia. 2007 Nov;21(11):2316-23 PMID: 17597807
  298. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12 PMID: 14993886
  299. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
    Bone Marrow Transplant. 2009 Feb;43(4):327-33 PMID: 18850014
  300. Allogeneic transplantation in lymphoma: current status.
    Haematologica. 2007 Nov;92(11):1533-48 PMID: 18024402
  301. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.
    N Engl J Med. 1994 Nov 10;331(19):1253-8 PMID: 7935682
  302. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2007 Dec;21(12):2540-4 PMID: 17611563
  303. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Blood. 2003 Jul 15;102(2):571-6 PMID: 12576330
  304. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
    Blood. 2008 Feb 1;111(3):1094-100 PMID: 18003886
  305. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
    Br J Haematol. 2009 Mar;144(5):794-5 PMID: 19036096
  306. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.
    Blood. 2002 Jul 15;100(2):397-405 PMID: 12091328
  307. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
    Exp Hematol. 2005 Mar;33(3):286-94 PMID: 15730852
  308. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 1998 Apr;29(3-4):301-13 PMID: 9684928
  309. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    J Clin Oncol. 2008 Nov 1;26(31):5094-100 PMID: 18711173
  310. Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukaemia following allogeneic transplantation.
    Clin Lab Haematol. 1996 Mar;18(1):45-6 PMID: 9118604
  311. Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
    Haematologica. 2006 Jun;91(6 Suppl):ECR16 PMID: 16785122
  312. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.
    Blood. 2008 Apr 15;111(8):4392-402 PMID: 17878399
  313. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2003 Dec;32(12):1159-63 PMID: 14647270
  314. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
    Clin Cancer Res. 2005 Jun 15;11(12):4504-11 PMID: 15958636
  315. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
    Cancer Res. 2003 Jan 1;63(1):36-8 PMID: 12517774
  316. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    J Clin Oncol. 2009 Aug 20;27(24):3951-8 PMID: 19620487
Article Info
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Abbr.
Biol Blood Marrow Transplant
ISSN
1523-6536
DOI
10.1016/j.bbmt.2010.08.001
Email
[email protected]
Published
2010-11-00
Epub
2010-00-10
Pages
1467-503
Language
English
Region
United States
NLM ID
9600628
PMCID
PMC2955517
Subset
IM
Grants
NCI NIH HHS · K24 CA117879 · United States
External Links
PubMed source DOI: 10.1016/j.bbmt.2010.08.001 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2